Sheu Chau-Chyun, Wang Chun-Chun, Hsu Jui-Sheng, Chung Wei-Shiuan, Hsu Hong-Yi, Shi Hon-Yi
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan, Republic of China.
Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan, Republic of China.
World J Oncol. 2024 Aug;15(4):550-561. doi: 10.14740/wjon1882. Epub 2024 Jul 5.
Domestic and foreign studies on lung cancer have been oriented to the medical efficacy of low-dose computed tomography (LDCT), but there is a lack of studies on the costs, value and cost-effectiveness of the treatment. There is a scarcity of conclusive evidence regarding the cost-effectiveness of LDCT within the specific context of Taiwan. This study is designed to address this gap by conducting a comprehensive analysis of the cost-effectiveness of LDCT and chest X-ray (CXR) as screening methods for lung cancer.
Markov decision model simulation was used to estimate the cost-effectiveness of biennial screening with LDCT and CXR based on a health provider perspective. Inputs are based on probabilities, health status utility (quality-adjusted life years (QALYs)), costs of lung cancer screening, diagnosis, and treatment from the literatures, and expert opinion. A total of 1,000 simulations and five cycles of Markov bootstrapping simulations were performed to compare the incremental cost-utility ratio (ICUR) of these two screening strategies. Probability and one-way sensitivity analyses were also performed.
The ICUR of early lung cancer screening compared LDCT to CXR is $-24,757.65/QALYs, and 100% of the probability agree to adopt it under a willingness-to-pay (WTP) threshold of the Taiwan gross domestic product (GDP) per capita ($35,513). The one-way sensitivity analysis also showed that ICUR depends heavily on recall rate. Based on the prevalence rate of 39.7 lung cancer cases per 100,000 people in 2020, it could be estimated that LDCT screening for high-risk populations could save $17,154,115.
LDCT can detect more early lung cancers, reduce mortality and is cost-saving than CXR in a long-term simulation of Taiwan's healthcare system. This study provides valuable insights for healthcare decision-makers and suggests analyzing cost-effectiveness for additional variables in future research.
国内外关于肺癌的研究主要集中在低剂量计算机断层扫描(LDCT)的医学疗效上,但缺乏对其治疗成本、价值和成本效益的研究。在台湾的特定背景下,关于LDCT成本效益的确凿证据稀缺。本研究旨在通过对LDCT和胸部X光(CXR)作为肺癌筛查方法的成本效益进行全面分析来填补这一空白。
基于医疗服务提供者的视角,采用马尔可夫决策模型模拟来估计每两年进行一次LDCT和CXR筛查的成本效益。输入数据基于文献中的概率、健康状况效用(质量调整生命年(QALYs))、肺癌筛查、诊断和治疗成本以及专家意见。共进行了1000次模拟和五个周期的马尔可夫自举模拟,以比较这两种筛查策略的增量成本效用比(ICUR)。还进行了概率和单因素敏感性分析。
早期肺癌筛查中,LDCT与CXR相比的ICUR为-24,757.65美元/QALYs,在台湾人均国内生产总值(GDP)(35,513美元)的支付意愿(WTP)阈值下,100%的概率同意采用该方法。单因素敏感性分析还表明,ICUR在很大程度上取决于召回率。根据2020年每10万人中39.7例肺癌病例的患病率,可以估计对高危人群进行LDCT筛查可节省17,154,115美元。
在台湾医疗系统的长期模拟中,LDCT比CXR能检测出更多早期肺癌,降低死亡率且节省成本。本研究为医疗决策者提供了有价值的见解,并建议在未来研究中分析其他变量的成本效益。